<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070161</url>
  </required_header>
  <id_info>
    <org_study_id>REBACCCWFU-97100</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <nct_id>NCT00070161</nct_id>
  </id_info>
  <brief_title>Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor</brief_title>
  <official_title>Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such
      as thinking, attention, concentration, and memory) and may improve quality of life in
      patients who have undergone radiation therapy to the brain.

      PURPOSE: This phase II trial is studying how well donepezil or EGb761 works in improving
      neurocognitive function in patients who have undergone radiation therapy for primary brain
      tumor or brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the effect of donepezil or EGb761 on neurocognitive function in patients who
           underwent radiotherapy for a primary brain tumor or brain metastases at least 6 months
           before study registration.

      Secondary

        -  Determine the toxicity of these drugs in these patients.

        -  Determine the quality of life of patients treated with these drugs.

        -  Quantify the extent of radiation-induced white matter disease and temporal lobe atrophy
           in patients treated with these drugs.

      OUTLINE: This is an open-label, multicenter study.

        -  Group 1 (closed to accrual 10/09/03): Patients receive oral donepezil once daily for 24
           weeks.

        -  Group 2: Patients receive oral EGb761 three times daily for 24 weeks. In both groups
           (group 1 closed to accrual 10/09/03), treatment continues in the absence of unacceptable
           toxicity.

      In both groups (group 1 closed to accrual 10/09/03), quality of life and neurocognitive
      assessment is performed at baseline and at weeks 6 (group 1 only), 12, 24, and 30.

      Patients are followed at 6 weeks.

      PROJECTED ACCRUAL: A total of 70 patients (35 per treatment group) will be accrued for this
      study within 9.5 months. (Group 1 closed to accrual 10/09/03)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">68</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Radiation Toxicity</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EGb761</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cognitive assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following
             criteria:

               -  No radiographic evidence of disease

               -  Stable disease, defined as no tumor progression within the past 3 months

          -  Previously treated with 1 course of localized or whole brain radiotherapy of at least
             3,000 cGy at least 6 months before study registration

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 70-100%

        Life expectancy

          -  At least 30 weeks

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No concurrent chemotherapy

        Endocrine therapy

          -  Concurrent steroid therapy allowed if on stable or decreasing dose

        Radiotherapy

          -  See Disease Characteristics

          -  No concurrent cranial radiotherapy

        Surgery

          -  No concurrent surgery

        Other

          -  More than 3 months since prior donepezil or EGb761

          -  No concurrent donepezil (group 2 only)

          -  No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03)

          -  No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or
             enoxaparin) (group 2 only)

          -  No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine)

          -  No other concurrent therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward G. Shaw, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Western Regional, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Radiation Oncology Center at Rome</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, Rapp SR. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006 Mar 20;24(9):1415-20.</citation>
    <PMID>16549835</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation toxicity</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>adult tumors metastatic to brain</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult meningeal hemangiopericytoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>adult pineocytoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

